- Home
- PCRX vs HKD Comparison
PCRX vs HKD Comparison
Compare PCRX & HKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCRX | HKD |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 487.1M |
| IPO Year | 2011 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PCRX | HKD |
|---|---|---|
| Price | $26.30 | $1.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $32.86 | N/A |
| AVG Volume (30 Days) | ★ 916.7K | 452.9K |
| Earning Date | 11-06-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $716,791,000.00 | $87,436,000.00 |
| Revenue This Year | $6.24 | N/A |
| Revenue Next Year | $9.53 | N/A |
| P/E Ratio | $55.91 | ★ $11.76 |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $18.17 | $1.33 |
| 52 Week High | $27.64 | $5.47 |
Technical Indicators
Market Signals| Indicator | PCRX | HKD |
|---|---|---|
| Relative Strength Index (RSI) | 64.48 | 39.59 |
| Support Level | $25.48 | $1.33 |
| Resistance Level | $27.16 | $1.43 |
| Average True Range (ATR) | 1.00 | 0.08 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 77.18 | 12.89 |
Price Performance
Historical ComparisonAbout PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment, hotel operations, hospitality and VIP services segment and media and entertainment services. The company generates maximum revenue by providing financial digital solutions through its insurance brokerage services and other digital solutions services. Geographically, the company generates maximum revenue from Hong Kong and Singapore.